HomeCONGRESS

CONGRESS

View Category
Day 2

UMPIRE Trial: the polypill proves effective in treating high risk patients.

A polypill is an interesting strategy for cardiac patients requiring multiple drugs. This trial involved 2138 patients...
solaci -
Learn More
SOLACI Session

An interventional cardiologist`s perspective on endovascular therapy for AAA

Guering Eid-Lidt2013-03-09
solaci -
Learn More
SOLACI Session

CREST, ACT 1 and Other Trials

William A. Gray2013-03-09
solaci -
Learn More
Day 1

CPORT-E: Comparison of percutaneous treatment cost in hospitals with and without central vascular surgery.

A total of 18,273 patients receiving angioplasty in hospitals with or without central vascular surgery were followed...
solaci -
Learn More
Day 1

Artic Study: Bedside Platelet Function Monitoring to Reduce Events after DES Implantation .

Given the individual variability of response to antiplatelet therapies, measuring platelet function and designing tailored therapies could...
solaci -
Learn More
Day 3

PARTNER cohort A at three years, the benefit continues

The PARTNER Cohort A randomized 699 elderly patients, (mean age 84.1), with severe aortic stenosis for TAVI...
solaci -
Learn More
Day 3

ASTRONAUT: Aliskiren failed to show benefits in patients with acute heart failure

Hospitalization for heart failure, (HF), represents a major health problem with high rates of death or early...
solaci -
Learn More
Day 3

RELAX Study: Phosphodieserase-5 inhibitors showed no benefit in heart failure with preserved ventricular function.

Phosphodieserase-5 enzyme is activated in heart failure and can limit the beneficial effects of nitric oxide, (NO),...
solaci -
Learn More